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Status of this clarification 
1.1 This clarification should be read together with the NICE guideline on cannabis-based medicinal 
products, first published on 11 November 2019 (“the guideline”). Both the guideline, and this 
clarification, must be taken into account by healthcare professionals when making clinical 
judgements, and by NHS bodies. 
Scope 
2.1 This clarification relates to the interpretation of the aspect of the guideline concerned with the 
use of cannabis-based medicinal products to treat severe treatment-resistant epilepsy in children. 
(NICE has published separate technology appraisal guidance on cannabidiol with clobazam for 
treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome). 
2.2 In every case, healthcare professionals must properly interpret the guideline when making 
clinical judgements about the use of cannabis-based medicinal products. 
Interpretation of the guideline 
© NICE 2021. All rights reserved. Subject to Notice of rights. Page 1 of 2
3.1 The guideline made research recommendations for the use of unlicensed cannabis-based 
medicinal products for severe treatment-resistant epilepsy. The committee took the view, based on 
the evidence available at the time, that there was insufficient evidence of safety and effectiveness 
to support a population-wide practice recommendation (that is, a recommendation relating to the 
whole population of people with severe treatment-resistant epilepsy). 
3.2 The fact that NICE made no such population-wide recommendation should not however be 
interpreted by healthcare professionals as meaning that they are prevented from considering the 
use of unlicensed cannabis-based medicinal products where that is clinically appropriate in an 
individual case. Patients in this population can be prescribed cannabis-based medicinal products if 
the healthcare professional considers that that would be appropriate on a balance of benefit and 
risk, and in consultation with the patient, and their families and carers or guardian. 
3.3 There is no recommendation against the use of cannabis-based medicinal products. For more 
information about why the committee decided not to recommend against use of these products, 
see the rationale section of the guideline. 
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